RMC No. 129-2022 updates the VAT-exempt medicines list under the CREATE Act, removing certain mental health medicines and requiring businesses to apply 12% VAT immediately.

Businesses in the pharmaceutical sector, healthcare providers, and distributors must take immediate note: certain medicines previously exempt from VAT under Republic Act No. 11534 (CREATE Act) are now removed from the VAT-exempt list. This change impacts sales invoicing, VAT reporting, and compliance obligations.

What Changed

RMC No. 129-2022, issued on September 20, 2022, publishes the September 1, 2022 letter from the Food and Drug Administration (FDA) Director General Samuel A. Zacate. The circular endorses updates to the official


Leave a Comment

Your email address will not be published. Required fields are marked *